Cue Biopharma, Inc. experienced a decrease in collaboration revenue and an increase in net loss for the first quarter of 2025 compared to the same period last year. The company reported a net loss of $12.257 million and collaboration revenue of $0.421 million. Despite the losses, the company secured significant funding through a public offering and a new collaboration agreement with Boehringer Ingelheim International GmbH, which are expected to fund operations into Q2 2026.

Cue Biopharma reported a net loss of $9.496 million for the fourth quarter of 2024, with collaboration revenue at $1.576 million. The company focused on prioritizing autoimmune programs and advancing clinical data from oncology programs to support strategic partnerships.

Cue Biopharma reported its Q3 2024 financial results, featuring increased collaboration revenue and reduced research and development, and general and administrative expenses. The company highlighted positive updated data from Phase 1 trials of CUE-101 and CUE-102, along with the advancement of preclinical programs.

Cue Biopharma reported a collaboration revenue increase due to the Ono Pharmaceutical agreement and advancements in clinical trials for CUE-101 and CUE-102. The company's cash and cash equivalents are expected to fund operations into the first quarter of 2025.

Cue Biopharma reported collaboration revenue of $0.9 million for the first quarter of 2020. Research and development expenses were $9.9 million, and general and administrative expenses were $3.9 million. The company's net loss for the quarter was $12.818 million, or $0.48 per share.

Cue Biopharma reported collaboration revenue of $1.0 million for the fourth quarter of 2019, and cash and cash equivalents of $59.4 million as of December 31, 2019. The company focused on clinical development of CUE-101 and made progress on its Immuno-STAT™ Platform.